216 related articles for article (PubMed ID: 8098377)
1. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.
Tsai CM; Chang KT; Perng RP; Mitsudomi T; Chen MH; Kadoyama C; Gazdar AF
J Natl Cancer Inst; 1993 Jun; 85(11):897-901. PubMed ID: 8098377
[TBL] [Abstract][Full Text] [Related]
2. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines.
Tsai CM; Chang KT; Wu LH; Chen JY; Gazdar AF; Mitsudomi T; Chen MH; Perng RP
Cancer Res; 1996 Jan; 56(1):206-9. PubMed ID: 8548764
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Zhang L; Hung MC
Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
[TBL] [Abstract][Full Text] [Related]
4. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
5. Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells.
Tsai CM; Chang KT; Li L; Perng RP; Yang LY
Jpn J Cancer Res; 2000 Feb; 91(2):213-22. PubMed ID: 10761709
[TBL] [Abstract][Full Text] [Related]
6. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
7. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
Tan D; Deeb G; Wang J; Slocum HK; Winston J; Wiseman S; Beck A; Sait S; Anderson T; Nwogu C; Ramnath N; Loewen G
Diagn Mol Pathol; 2003 Dec; 12(4):201-11. PubMed ID: 14639106
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
10. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
11. MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs.
Giaccone G; van Ark-Otte J; Rubio GJ; Gazdar AF; Broxterman HJ; Dingemans AM; Flens MJ; Scheper RJ; Pinedo HM
Int J Cancer; 1996 Jun; 66(6):760-7. PubMed ID: 8647646
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells.
Tsai CM; Levitzki A; Wu LH; Chang KT; Cheng CC; Gazit A; Perng RP
Cancer Res; 1996 Mar; 56(5):1068-74. PubMed ID: 8640763
[TBL] [Abstract][Full Text] [Related]
13. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene.
Evers BM; Rady PL; Sandoval K; Arany I; Tyring SK; Sanchez RL; Nealon WH; Townsend CM; Thompson JC
Ann Surg; 1994 Jun; 219(6):596-601; discussion 602-4. PubMed ID: 7911296
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer.
Uchiyama M; Usami N; Kondo M; Mori S; Ito M; Ito G; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Minna JD; Shimokata K; Sekido Y
Int J Cancer; 2003 Dec; 107(6):962-9. PubMed ID: 14601056
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
19. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
[TBL] [Abstract][Full Text] [Related]
20. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
